KRAS G12C
1 drugsPredictive biomarker for patient selection in 1 indication
1
Approved Drugs
1
Indications
1
Companies
KRAS G12C is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 1 indication including Metastatic Colorectal Cancer. Explore the targeted therapies, indications, testing methods, and companies developing KRAS G12C drugs below.
Search KRAS G12C Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting KRAS G12C
| Drug | Company | Therapeutic Area |
|---|---|---|
| VECTIBIX | Amgen | Oncology |
KRAS G12C Indications
Metastatic Colorectal Cancer